chugai

ACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. In these patients, ACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate measured by HAQ-DI score.

ACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adult patients not previously treated with MTX. In these patients, ACTEMRA can be given as monotherapy in case of intolerant to MTX or where continued treatment with MTX is inappropriate. ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray when given in combination with methotrexate.